Bio Plus Co

Bio Plus Co EBIT Margin

The EBIT Margin (Operating Margin) of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 16.51 %. In the previous year, EBIT Margin (Operating Margin) was 35.64 % — a change of -53.68% (lower).

EBIT Margin

16.51 %

YoY

-53.68%

Last updated:

EBIT Margin (Operating Margin) of Bio Plus Co is 2025 16.51 % . EBIT Margin (Operating Margin) of Bio Plus Co was 2024 35.64 % . It decreases by -53.68% lower compared to the previous year.

Bio Plus Co's operating (EBIT) margin stands at 16.5%, down from 44.5% several years earlier.

The Bio Plus Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
36.00 KRW
Jan 1, 2019
39.96 KRW
Jan 1, 2020
50.59 KRW
Jan 1, 2021
44.53 KRW
Jan 1, 2022
44.51 KRW
Jan 1, 2023
43.10 KRW
Jan 1, 2024
35.64 KRW
Jan 1, 2025
16.51 KRW
The Bio Plus Co EBIT Margin history
YEAREBIT MarginYoY
16.51 %-53.68%
35.64 %-17.32%
43.10 %-3.16%
44.51 %-0.05%
44.53 %-11.98%
50.59 %+26.61%
39.96 %+10.99%
36.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

EBIT Margin (Operating Margin) of Bio Plus Co is 16.51 % in 2025.

EBIT Margin (Operating Margin) of Bio Plus Co changed from 35.64 % to 16.51 %, representing a -53.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Bio Plus Co

All Key Metrics — Bio Plus Co